PolyPid Ltd reports results for the quarter ended March 31 - Earnings Summary
14/05/2025 14:32
PolyPid Ltd PYPD.OQ reported a quarterly adjusted loss of 70 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.37. The mean expectation of three analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -84 cents to -75 cents per share. Reported revenue was zero; analysts expected zero. PolyPid Ltd's reported EPS for the quarter was a loss of 70 cents. The company reported a quarterly loss of $8.27 million. PolyPid Ltd shares had held steady so far this quarter and lost 10.9% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 5.1% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for PolyPid Ltd is $11.00 This summary was machine generated from LSEG data May 14 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.80 | -0.70 | Beat |
| Dec. 31 2024 | -0.88 | -1.09 | Missed |
| Sep. 30 2024 | -1.00 | -1.22 | Missed |
| Jun. 30 2024 | -1.30 | -1.25 | Beat |
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA